Factors Associated to Success of Hepatitis C Therapy
Overview
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- UPECLIN HC FM Botucatu Unesp
- Enrollment
- 100
- Locations
- 1
Overview
Brief Summary
The aim of this study is to evaluate the sustained virologic response (RVS) in HVC patients treated with pegylated-interferon or conventional-interferon and ribavirin, and to investigate the associated factors with RVS, by means of retrospective analysis.
Detailed Description
Chronic hepatitis C virus(HVC) is a major public-health problem since it presents a long phase of clinical latency which makes its early diagnosis difficult and results in the development of a large number of cases to complications such as cirrhosis, hepatic insufficiency and hepatocarcinoma. In Brazil, it is estimated three million estimated cases to 52 thousand reports. The aim of this study is to evaluate the sustained virologic response (RVS) in HVC patients treated with pegylated-interferon or conventional-interferon and ribavirin, and to investigate the associated factors with RVS, by means of retrospective analysis.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Retrospective
Eligibility Criteria
- Ages
- 18 Years to 70 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •HVC patients that received specific treatment with pegylated-interferon or conventional-interferon, and ribavirin
Exclusion Criteria
- •No HVC infection or treatment
Arms & Interventions
HVC Patients
HVC patients attended in SAE e HD.
Intervention: pegylated-interferon, conventional-interferon, ribavirin (Drug)